Methods and compositions for treating gain-of-function disorders using RNA interference
The present invention relates to novel methods for treating dominant gain-of-function diseases. The invention provides methods for targeting regions of the copper zinc superoxide dismutase (SOD1), which causes inherited amyotrophic lateral sclerosis (ALS), with RNAi agent. The invention further provides RNAi resistant replacement genes containing mismatches with their respective RNAi agent s. The invention also provides for vectors that express RNAi agent and RNAi resistant replacement gene of the present invention.
1. A nucleic acid agent comprising, a first polynucleotide sequence encoding an RNAi agent specific for a human SOD1 gain-of function target mRNA, and a second polynucleotide sequence encoding a RNAi resistant replacement gene,
wherein the RNAi agent comprises an antisense strand having sufficient sequence complementarity to the gain-of function target mRNA to induce cleavage of the target mRNA, and a sense strand complementary to said antisense strand,
wherein the RNAi replacement gene comprises a nucleotide seciuence encoding a wild-type human SOD1, the nucleotide sequence encoding wild-type human SOD1 comprising a sufficient number of silent mutations such that the mRNA encoded by the replacement gene is resistant to cleavage by the RNAi agent, and
wherein the antisense strand is encoded by a nucleic acid comprising SEQ ID NO:2 or SEQ ID NO:6.
2. A nucleic acid agent comprising, a first polynucleotide sequence encoding an RNAi agent specific for a human SOD1 gain-of function target mRNA, and a second polynucleotide sequence encoding a RNAi resistant replacement gene,
wherein the RNAi agent comprises an antisense strand having sufficient sequence complementarity to the gain-of function target mRNA to induce cleavage of the target mRNA, and a sense strand complementary to said antisense strand,
wherein the RNAi replacement gene comprises a nucleotide sequence encoding a wild-type human SOD1, the nucleotide seciuence encoding wild-type human SOD1 comprising a sufficient number of silent mutations such that the mRNA encoded by the replacement gene is resistant to cleavage by the RNAi agent, and
wherein the RNAi resistant replacement gene comprises SEQ ID NO:3 or SEQ ID NO:85.
3. The nucleic acid agent of claim 1 or 2 , wherein the sense strand is encoded by a nucleic acid comprising SEQ ID NO:1, and the antisense strand is encoded by a nucleic acid comprising SEQ ID NO:2.
4. The nucleic acid agent of claim 1 or 2 , wherein the sense strand comprises about 22 nucleotides and the antisense strand comprises 22 nucleotides.
5. The nucleic acid agent of claim 1 or 2 , wherein the RNAi agent is expressed as an shRNA.
6. The nucleic acid agent of claim 1 or 2 , wherein the RNAi resistant replacement gene contains 3 or more silent mutations.
7. A composition comprising the nucleic acid agent of claim 1 or 2 and a pharmaceutically acceptable carrier.
8. A kit comprising reagents for activating target-specific RNA interference (RNAi) in a cell or organism, the kit comprising the nucleic acid agent of claim 1 or 2 , and instructions for use.
9. A cassette or vector comprising the nucleic acid agent of claim 1 or 2 .
10. The cassette or vector of claim 9 , further comprising conditional expression sequences.
11. An isolated cell comprising the cassette or vector of claim 9 .
12. The cell of claim 11 , wherein the cell is of mammalian origin.
13. The cell of claim 11 , wherein the cell is of human origin.
14. The nucleic agent of claim 1 or 2 , wherein the RNAi agent targets a region in the gain-of function target mRNA which is common to both mutant and wild-type SOD1.
15. The nucleic acid agent of 1 or 2 , wherein the RNAi resistant replacement gene contains 4 or more silent mutations.
16. The nucleic acid agent of 1 or 2 , wherein the RNAi resistant replacement gene contains 5 or more silent mutations.
17. The nucleic acid agent of 1 or 2 , wherein the RNAi resistant replacement gene contains 6 or more silent mutations.